Skip to main content

Advertisement

SpringerLink
Log in

Renal insufficiency in patients with multiple myeloma

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Renal insufficiency in patients with multiple myeloma represents a major challenge for the treating physician. In patients with etiologically unclear renal failure it is important to consider multiple myeloma as a possible cause of such renal failure. The diagnosis and treatment of these patients is interdisciplinary, in cooperation with hemato-oncologists, radiologists, nephrologists and intensive care specialists. The main goal of all treatment methods is the rapid reduction of pathological free light chains in the serum, resulting in an improvement of renal function. Equally important is the avoidance of nephrotoxic drugs and iodinated contrast agents in patients with renal insufficiency and multiple myeloma. A few new drugs have been used in the systemic treatment of patients with multiple myeloma (MM) and renal failure with much success, especially the beneficial use of pomalidomide is interesting and other drugs will follow soon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Badros AZ, Vij R, Martin T, Zonder JA, et al. Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety. Leukemia. 2013;27:1707–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Baz RC, Martin TG 3rd, Lin HY, et al. Randomized multicenter phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561–8-

    Article  CAS  PubMed  Google Scholar 

  3. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17.

    Article  CAS  PubMed  Google Scholar 

  4. Berdeja J. Pharmacokinetics and safety of Elotuzumab combined with Lenalidomide and Dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–38.

    Article  PubMed  Google Scholar 

  5. Bridoux F, Pegourie B, Meunier KA, Royer B, Joly B, Lamy T, Kolb B, Benboubker L, Arnulf B, Jaccard A, Chevret S, Fermand JP. Treatment of myeloma cast Nephropathy (MCN): A randomized trial comparing intensive Haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a Bortezomib-based regimen (the MYRE study, by the Intergroupe Francophone du Myélome (IFM) and the french society of Nephrology (SFNDT)). Blood. 2016;128(22):978.

    Google Scholar 

  6. Davenport A, Merlini G. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrol Dial Transplant. 2012;27:3713–8.

    Article  PubMed  Google Scholar 

  7. Dimopoulos MA, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1.

    Article  Google Scholar 

  8. Dimopoulos MA, Roussou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Bloodadvances. 2017;7:449–54.

    Google Scholar 

  9. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701–5.

    Article  CAS  PubMed  Google Scholar 

  10. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22:1485–93.

    Article  CAS  PubMed  Google Scholar 

  11. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195–200.

    Article  CAS  PubMed  Google Scholar 

  12. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, et al. Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

    Article  CAS  PubMed  Google Scholar 

  14. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215–24.

    Article  CAS  PubMed  Google Scholar 

  15. Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):232–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gupta N, et al. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. Br J Haematol. 2016;174(5):748–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hutschison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials. 2008;9:55.

    Article  Google Scholar 

  18. Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study. Blood. 2013;122(16):2799–806.

    Article  CAS  PubMed  Google Scholar 

  19. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823–8.

    Article  CAS  PubMed  Google Scholar 

  20. Ludwig H, Durie BGM, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ludwig H, Drach J, Graf H, Lang A, Meran JG, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92:1411–4.

    Article  CAS  PubMed  Google Scholar 

  22. Ludwig H, Adam Z, Hajek R, et al. Light chain–induced acute renal failure Can be reversed by Bortezomib-Doxorubicin-Dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol. 2010;28:4635–41.

    Article  CAS  PubMed  Google Scholar 

  23. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28:981–92.

    Article  CAS  PubMed  Google Scholar 

  24. Ludwig H, Rauch E, Kuehr T, et al. Lenalidomide and dexamethasone for acute light chain-induced renal failure: A phase II study. Haematologica. 2015;100(3):385–391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. San Miguel JF. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment? Haematologica. 2014;99(1):140–47.

    Article  Google Scholar 

  26. Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–45.

    Article  CAS  PubMed  Google Scholar 

  27. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.

    Article  CAS  PubMed  Google Scholar 

  28. Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:999–1009.

    Article  Google Scholar 

  29. Sonneveld P, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Medical Department, Ludwig Boltzmann Institute for Stem Cell Transplantation, Danube Hospital (SMZ Ost Wien), Langobardenstraße 122, 1220, Vienna, Austria

    Boris Bozic,  Sophie Hölbling,  Vanessa Völkel &  Christian Sebesta

Authors
  1. Boris Bozic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Hölbling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vanessa Völkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Sebesta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Bozic.

Ethics declarations

Conflict of interest

B. Bozic, S. Hölbling, V. Völkel and C. Sebesta declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bozic, B., Hölbling, S., Völkel, V. et al. Renal insufficiency in patients with multiple myeloma. memo 10, 151–158 (2017). https://doi.org/10.1007/s12254-017-0343-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-017-0343-3

Keywords

Search

Navigation